Ubrogepant
Modify Date: 2024-01-02 18:59:55
Ubrogepant structure
|
Common Name | Ubrogepant | ||
|---|---|---|---|---|
| CAS Number | 1374248-77-7 | Molecular Weight | 549.54400 | |
| Density | 1.45±0.1 g/cm3(Predicted) | Boiling Point | 729.4±60.0 °C(Predicted) | |
| Molecular Formula | C29H26F3N5O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of UbrogepantUbrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine[1]. |
| Name | (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide |
|---|---|
| Synonym | More Synonyms |
| Description | Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine[1]. |
|---|---|
| Related Catalog | |
| Target |
MK-1602[1] |
| References |
| Density | 1.45±0.1 g/cm3(Predicted) |
|---|---|
| Boiling Point | 729.4±60.0 °C(Predicted) |
| Molecular Formula | C29H26F3N5O3 |
| Molecular Weight | 549.54400 |
| Exact Mass | 549.19900 |
| PSA | 111.27000 |
| LogP | 4.12840 |
| (3'S)-N-((3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro(cyclopenta(b)pyridine-6,3'-pyrrolo(2,3-b)pyridine)-3-carboxamide |
| Spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide,1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl)-2'-oxo-,(3'S) |
| Ubrogepant [USAN] |
| MK-1602 |
| Ubrogepant |